文献速递传染病防控与疫情报告卫生政策与健康促进

在达到不同新冠疫苗接种覆盖率水平前后维持佩戴口罩:一项建模研究

Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study.
PubMed 文献 · Lancet Public Health · 2022-03-08

该计算模拟模型研究模拟美国人群和SARS-CoV-2传播,比较在达到目标疫苗接种覆盖率(70-90%)前使用与不使用口罩的情景。结果显示,维持口罩使用(截至2020年3月至7月美国观察到的覆盖率)直至达到目标接种覆盖率具有成本效果,且在多数情景下节省成本;在达到目标覆盖率后继续维持口罩使用约2-10周也具有成本效果。

要点

  • 维持口罩使用直至达到目标疫苗接种覆盖率(70-90%)具有成本效果,且在多数情景下节省成本。
  • 在达到目标覆盖率后继续维持口罩使用约2-10周仍具有成本效果,冬季比夏季所需时间更长。
  • 病毒传播性增加或疫苗有效性降低的情景只会增加维持口罩使用的成本节省或成本效果。

核心结论

  • 研究强烈支持在达到各种最终疫苗接种覆盖率水平时及之后短时间內维持口罩使用,因为维持口罩使用不仅具有成本效果,甚至可能节省成本。
  • 奥密克戎变异株的出现以及未来可能更具传播性或降低疫苗有效性的变异株只会增加口罩的价值。

研究设计与样本

  • 计算模拟模型研究,开发并使用了代表美国人群和SARS-CoV-2传播的蒙特卡洛模拟模型。
  • 模拟实验比较了在达到给定最终疫苗接种覆盖率之前使用口罩与不使用口罩的情况。
  • 情景变化了目标疫苗接种覆盖率(70-90%)、达到这些覆盖率的日期(2022年1月1日至2022年7月1日)以及人群停止佩戴口罩的日期。

主要发现

  • 维持口罩使用(截至2020年3月至2020年7月美国观察到的覆盖率)直至达到目标疫苗接种覆盖率,在几乎所有探索的情景中,从社会视角和第三方支付者视角均具有成本效果,且在多数情况下节省成本。
  • 当每人每天口罩成本≤1.25美元时,使用口罩被估计具有成本效果且通常节省成本。
  • 在所有情景中,在达到目标疫苗接种覆盖率(70-90%)的日期之后继续维持口罩使用约2-10周被估计具有成本效果,且当目标覆盖率在冬季而非夏季达到时,这一额外持续时间更长。
  • 可能增加病毒传播性的因素(如德尔塔[B.1.617.2]和奥密克戎[B.1.1.529]变异株的出现)、或降低疫苗有效性的因素(如免疫力减弱或逃逸变异株)、或增加特定人群社会互动的因素,只会增加维持口罩使用带来的成本节省或成本效果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Face mask wearing has been an important part of the response to the COVID-19 pandemic. As vaccination coverage progresses in countries, relaxation of such practices is increasing. Subsequent COVID-19 surges have raised the questions of whether face masks should be encouraged or required and for how long. Here, we aim to assess the value of maintaining face masks use indoors according to different COVID-19 vaccination coverage levels in the USA. METHODS: In this computational simulation-model study, we developed and used a Monte Carlo simulation model representing the US population and SARS-CoV-2 spread. Simulation experiments compared what would happen if face masks were used versus not used until given final vaccination coverages were achieved. Different scenarios varied the target vaccination coverage (70-90%), the date these coverages were achieved (Jan 1, 2022, to July 1, 2022), and the date the population discontinued wearing face masks. FINDINGS: Simulation experiments revealed that maintaining face mask use (at the coverage seen in the USA from March, 2020, to July, 2020) until target vaccination coverages were achieved was cost-effective and in many cases cost saving from both the societal and third-party payer perspectives across nearly all scenarios explored. Face mask use was estimated to be cost-effective and usually cost saving when the cost of face masks per person per day was ≤US$1·25. In all scenarios, it was estimated to be cost-effective to maintain face mask use for about 2-10 weeks beyond the date that target vaccination coverage (70-90%) was achieved, with this added duration being longer when the target coverage was achieved during winter versus summer. Factors that might increase the transmissibility of the virus (eg, emergence of the delta [B.1.617.2] and omicron [B.1.1.529] variants), or decrease vaccine effectiveness (eg, waning immunity or escape variants), or increase social interactions among certain segments of the population, only increased the cost savings or cost-effectiveness provided by maintaining face mask use. INTERPRETATION: Our study provides strong support for maintaining face mask use until and a short time after achieving various final vaccination coverage levels, given that maintaining face mask use can be not just cost-effective, but even cost saving. The emergence of the omicron variant and the prospect of future variants that might be more transmissible and reduce vaccine effectiveness only increases the value of face masks. FUNDING: The Agency for Healthcare Research and Quality, the National Institute of General Medical Sciences, the National Science Foundation, the National Center for Advancing Translational Sciences, and the City University of New York.

来源:Lancet Public Health,查看原文。版权归原作者所有。

引用

  1. Bartsch SM, O'Shea KJ, Chin KL, et al. Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study. Lancet Public Health. 2022. PMID: 35276093. doi:10.1016/S2468-2667(22)00040-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。